Drug intelligence / Profile preview

Simiao Sanjie granules

Development stage: Unknown
Lead developer: Guang'anmen Hospital
Administration: Oral

Overview

Simiao Sanjie granules is a Traditional Chinese Medicine (TCM) herbal formulation developed by Guang'anmen Hospital of the China Academy of Chinese Medical Sciences. It is primarily indicated for the management of high-risk subsolid pulmonary nodules (SSNs), which are clinical precursors or early manifestations of lung adenocarcinoma. The formulation is designed based on TCM principles to "dissipate nodules" and "resolve phlegm," aiming to stabilize or reduce the size of pulmonary nodules and mitigate the risk of progression to lung cancer. It is currently undergoing clinical evaluation to determine its safety and efficacy in patients with persistent subsolid nodules.

Other names: 四妙散结颗粒Simiao Sanjie DecoctionSimiao Sanjie

Beyond the preview

Go deeper on Simiao Sanjie granules.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Simiao Sanjie granules.

Explore the full profile